ZETAGEN THERAPEUTICS, INC.
New Form D on file · 2025-01-23 · the record
Before you sell to, join or invest in ZETAGEN THERAPEUTICS, INC.
MentionFox check on ZETAGEN THERAPEUTICS, INC.: only 2 sources on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/zetagen-therapeutics-inc-form-d-25000001
Check ZETAGEN THERAPEUTICS, INC. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
ZETAGEN THERAPEUTICS, INC. filed an amended Form D with the Securities and Exchange Commission on 2025-01-23.
ZETAGEN THERAPEUTICS, INC. filed an amended Form D notice of an exempt securities offering with the SEC on January 23, 2025. The filing reports $12.91M sold. Its industry group is Pharmaceuticals. It names Nikhil Thakur, MD (Executive Officer, Director), Peter Finn (Executive Officer), Joe Loy (Executive Officer, Director) (SEC Form D/A, January 23, 2025).
Sell to companies like ZETAGEN THERAPEUTICS, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
88 companies raised this week, 1 had other signals.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| fal - Features & Labels, Inc. | $1B | AI and software |
| fal - Features & Labels, Inc. | $350M | AI and software |
| SIERRA INTERNATIONAL NETWORK INC | $300M | AI and software |
| Zai Lab Ltd | $250M | Biotech |
| Databento Inc. | $100M | AI and software |
Is this your company?
New Form D on file · 2025-01-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ZETAGEN THERAPEUTICS, INC.
Free to see. No signup.
More on the people and the money behind ZETAGEN THERAPEUTICS, INC., from the filings we hold.
Get an email when ZETAGEN THERAPEUTICS, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ZETAGEN THERAPEUTICS, INC. raises, hires or launches. No email unless you switch it on.
Watch ZETAGEN THERAPEUTICS, INC. →Get the full cited report on ZETAGEN THERAPEUTICS, INC.
What the filing shows about ZETAGEN THERAPEUTICS, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ZETAGEN THERAPEUTICS, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The weeks after a raise are when investors, other founders and press look ZETAGEN THERAPEUTICS, INC. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on ZETAGEN THERAPEUTICS, INC.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.
The filing gives ZETAGEN THERAPEUTICS, INC.'s address as 841 East Fayette Street, Syracuse, NY 13210.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for ZETAGEN THERAPEUTICS, INC. →
Amended on 2025-11-12: the offering size changed from $6,173,828 to $12,999,998; the amount sold changed from $83,186 to $12,908,022; the number of investors changed from 1 to 35. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on ZETAGEN THERAPEUTICS, INC. See pricing
ZETAGEN THERAPEUTICS, INC. is a registered filer with the SEC (CIK 1730728) and has filed since 2023-02-06. 3 filings are on record, the latest on 2025-11-12.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
ZETAGEN THERAPEUTICS, INC.'s Form D of 2025-01-23 names Nikhil Thakur, MD, Peter Finn, Joe Loy and 3 more as its officers, directors or promoters.
Its new offerings report $9.72M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Some of the proceeds of the offering will be used for executive compensation in the normal course of business.
Nikhil Thakur, MD is named as Executive Officer and Director on the Form D that ZETAGEN THERAPEUTICS, INC. filed with the SEC on 23 January 2025, one of 6 people that filing names.
Peter Finn is named as Executive Officer on the Form D that ZETAGEN THERAPEUTICS, INC. filed with the SEC on 23 January 2025, one of 6 people that filing names.
Joe Loy is named as Executive Officer and Director on the Form D that ZETAGEN THERAPEUTICS, INC. filed with the SEC on 23 January 2025, one of 6 people that filing names.
Donald Brown is named as Director on the Form D that ZETAGEN THERAPEUTICS, INC. filed with the SEC on 23 January 2025, one of 6 people that filing names.
Ashok Kaveeshwar is named as Director on the Form D that ZETAGEN THERAPEUTICS, INC. filed with the SEC on 23 January 2025, one of 6 people that filing names.
Richard Warburg is named as Director on the Form D that ZETAGEN THERAPEUTICS, INC. filed with the SEC on 23 January 2025, one of 6 people that filing names.
6 people named on the filing — 3 holding an executive role and 3 as directors only.
Named as of the 2025-01-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about ZETAGEN THERAPEUTICS, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ZETAGEN THERAPEUTICS, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ZETAGEN THERAPEUTICS, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ZETAGEN THERAPEUTICS, INC.You get an alert in MentionFox the next time this company shows up.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for ZETAGEN THERAPEUTICS, INC.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

https://mentionfox.com/funding/zetagen-therapeutics-inc-form-d-25000001